Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma
- 28 February 2005
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 32, 36-43
- https://doi.org/10.1053/j.seminoncol.2005.01.012
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-UpJournal of Clinical Oncology, 2004
- Rituximab plus chemotherapy in follicular and mantle cell lymphomasSeminars in Oncology, 2003
- Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood, 2003
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.Journal of Clinical Oncology, 1998
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993